Gastroparesis and Parkinson’s Disease
A 82 year old male has a medical history of osteoarthritis, diabetes, BPH, gastroparesis and Parkinson’s disease. He is complaining of nausea and stomach upset after meals. Current medications include:
- Sinemet 25/100 mg 2 tablet three times daily
- Requip 0.5 mg BID
- Protonix 40 mg once daily
- Aspirin 81 mg daily
- oxybutynin 5 mg TID
- Diphenhydramine 50 mg HS
- Metformin 500 mg BID
- Acetaminophen 500 mg PRN
- Atorvastatin 10 mg daily
- Senna S 1 BID
This is a situation set up for the classic prescribing cascade. We have a new or exacerbated symptom of possible gastroparesis. The most common medication I see used in the setting of gastroparesis is metoclopramide. The major issue with metoclopramide is that it does block dopamine receptors and could exacerbate this gentleman’s Parkinson’s disease.
What I would like to address first is the use of the anticholinergics. Remember that anticholinergics can slow down the GI tract and possibly contribute to constipation and/or gastroparesis. Identifying why this patient is using diphenhydramine (likely for insomnia) and finding an alternative would be an appropriate consideration. Also looking at BPH and how/why this patient is on the oxybutynin would be another important aspect in trying to rule out drug induced gastroparesis.
Love the blog? Get a free gift simply for following! Over 4,000 medication loving healthcare professional have taken advantage of this!
3 thoughts on “Gastroparesis and Parkinson’s Disease”
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Try domperidone..better than metoclopramide for PK patients. Sure, things like reducing or stopping the Benadryl for sleep and changing the oxybutynin to a safer urinary antimuscarininc like Detrol are good pharmacy practices to pursue.
Patient is missing an ACE or ARB for Diabetes
Last time I checked, domperidone was not an approved drug in the United States, and physicians who want to prescribe have to request an expanded access investigational new drug application.